Feasibility, safety, efficacy and immunogenicity of MUC1 CEA ERBB2 telomerase BIRC5 MAGEA1 RNA vaccine in patients with stage IV renal cell carcinoma.

Trial Profile

Feasibility, safety, efficacy and immunogenicity of MUC1 CEA ERBB2 telomerase BIRC5 MAGEA1 RNA vaccine in patients with stage IV renal cell carcinoma.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Jul 2014

At a glance

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top